Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

295
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
295
Bone Disorders01:29

Bone Disorders

4.8K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
4.8K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

546
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
546
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.3K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

407
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
407
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

580
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
580

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of an automated landmarking tool for the femur in dual-energy X-ray absorptiometry scans using contour-based image analysis.

JBMR plus·2026
Same author

Optimal Perfusion Targets in Cardiogenic Shock.

JACC. Advances·2024
Same author

Automatic Radar-Based Step Length Measurement in the Home for Older Adults Living with Frailty.

Sensors (Basel, Switzerland)·2024
Same author

Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale·2022
Same author

Inotrope and vasopressor use in cardiogenic shock: what, when and why?

Current opinion in critical care·2022
Same author

Relationship between Serum 25-Hydroxyvitamin D Level and Risk of Recurrent Stroke.

Nutrients·2022

Related Experiment Videos

Glucocorticoid induced osteoporosis.

Kira Hu1, Jonathan D Adachi1

  • 1a Department of Medicine , McMaster University , Hamilton , ON , Canada.

Expert Review of Endocrinology & Metabolism
|May 17, 2019
PubMed
Summary

Glucocorticoid-induced osteoporosis is common, yet underdiagnosed. Early intervention with bisphosphonates, vitamin D, and calcium is recommended, with alternative treatments available for bone health.

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Glucocorticoid-induced osteoporosis is the leading secondary cause of osteoporosis.
  • Patients on glucocorticoids often lack skeletal health evaluation.
  • Glucocorticoids negatively impact bone cells, increasing resorption and hindering formation.

Purpose of the Study:

  • To review the mechanism of action and efficacy of various osteoporosis treatments.
  • To highlight the importance of pharmacologic prevention and treatment for patients on glucocorticoids.

Main Methods:

  • Literature search conducted in PubMed in November 2018.
  • 492 articles identified, with 45 included in the review.

Main Results:

Keywords:
Glucocorticoidbisphosphonatedenosumabosteoporosisteriparatide

Related Experiment Videos

  • Bone loss and fracture risk increase early in glucocorticoid treatment, peaking within 6 months.
  • Bone density loss is dose-dependent on glucocorticoid dosage.
  • Oral bisphosphonates with vitamin D and calcium are first-line treatments; alternatives like IV bisphosphonates, anabolic agents, and denosumab also show efficacy.

Conclusions:

  • Pharmacologic interventions are crucial for managing glucocorticoid-induced osteoporosis.
  • Various treatment options exist, with oral bisphosphonates as a primary choice.
  • Future research should focus on the safety and fracture-reducing capabilities of alternative therapies.